AGP Executive Report
Last update: 8 hours agoDrug Policy Crossroads (Czechia): Czech experts warn that shifting coordination of the country’s drug policy from the Office of the Government to the Ministry of Health could weaken the long-running, cross-sector model that has helped keep HIV/hepatitis C and opioid-related deaths comparatively low. Rare Disease Funding (Prague): At ECRD 2026 in Prague, speakers say Europe’s bottleneck is less about science and more about funding and the complexity of getting therapies to patients, with calls to rethink evidence generation for small populations. Cancer Research (EU/Genmab): Genmab reports new EHA Congress data on epcoritamab for elderly, newly diagnosed diffuse large B-cell lymphoma patients ineligible for standard chemo, including high response and complete response rates in fixed-duration regimens. Local Health Infrastructure (Vietnam): Vietnam’s Health Ministry pushes to finish the second facility of Bach Mai Hospital by end-June 2026, citing licensing completion and remaining technical and contracting steps. Infectious Disease Lab Breakthrough (Prague/Israel): Czech and Israeli scientists recreated in a test tube how SARS‑CoV‑2 evolved toward Omicron-like receptor-binding traits, aiming to improve forecasts of future waves. Public Health & Safety (Brussels): Brussels plans a full ban on rental electric scooters from 2024 onward, citing rising injuries and blocked sidewalks—an issue already tackled by cities including Prague.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.